Is Werewolf Therapeutics, Inc. (HOWL) a Buy, Sell, or Hold?
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
$0.3441 USD
$0.0 (0.76%)
- Volume
- 1.32M
- Average Volume
- 651.79K
- Market Capitalization
- $16.72M
- P/E Ratio
- -0.28
- Dividend Yield
- 0.00%
- Price Target
- $6.50
- Year High
- $2.38
- Year Low
- $0.27
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.27
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel J. Hicklin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HOWL |
| CUSIP | 95075A107 |
| CIK | 0001785530 |
| Web | https://werewolftx.com |
| Phone | 617 952 0555 |
| Currency | USD |
| Employees | 14 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.09 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.27 |
| Quick Ratio | 1.27 |
| Cash Ratio | 1.21 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.07 |
| Price / Cash Flow | -0.32 |
| Price / Book | 1.37 |
Price Target and Rating
| Average Stock Price Forecast | $6.50 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -94.71% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.33 |
| Trailing P/E Ratio | -0.28 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-60.82M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -208.23% |
| Return on Assets | -96.97% |
Financials Score
| AltmanZ Score | -14.26 |
| Piotroski Score | 2.00 |
| Working Capital | 10.22M |
| Total Assets | 58.02M |
| Ebit | -50.89M |
| Market Cap | 16.6M |
| Total Liabilities | 45.82M |
Poll Results
About Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is ... progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 16:05:00
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the first quarter ended March 31, 2026.
Frequently Asked Questions
-
What is the current Werewolf Therapeutics, Inc. (HOWL) stock price?
-
Werewolf Therapeutics, Inc.(NASDAQ:HOWL) stock price is $0.3441 in the last trading session. During the trading session, HOWL stock reached the peak price of $2.38 while $0.27 was the lowest point it dropped to. The percentage change in HOWL stock occurred in the recent session was 0.76% while the dollar amount for the price change in HOWL stock was $0.0.
-
HOWL's industry and sector of operation?
-
The NASDAQ listed HOWL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HOWL?
-
Daniel J. Hicklin | Founder, Chief Executive Officer, President, Secretary & Director
Michael Urban | VP of Finance, Corporate Controller, Principal Financial Officer & Principal Accounting Officer
Steven H. Bloom | Chief Business Officer
|
| -
How many employees does HOWL have?
-
Number of HOWL employees currently stands at 14. HOWL operates from 1030 Massachusetts Avenue, Watertown, MA 02138, US.
-
Link for HOWL official website?
-
Official Website of HOWL is: https://werewolftx.com
-
How do I contact HOWL?
-
HOWL could be contacted at phone #617 952 0555 and can also be accessed through its website. HOWL operates from 1030 Massachusetts Avenue, Watertown, MA 02138, US.
-
How many shares of HOWL are traded daily?
-
The average number of HOWL shares traded daily for last 3 months was 651.79K.
-
What is the market cap of HOWL currently?
-
The market value of HOWL currently stands at $16.72M with its latest stock price at $0.3441